Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts

Rodríguez-Tudela, Juan Luis; Barchiesi, Francesco; Billé, Jacques; Chryssanthou, Erja; Cuenca‐Estrella, Manuel; Denning, David W.; Donnelly, J. Peter; Dupont, B.; Fegeler, W.; Moore, Caroline B.; Richardson, Malcolm; Verweij, Paul E.

doi:10.1046/j.1469-0691.2003.00789.x

Cited by 162 publications

(115 citation statements)

References 12 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…When the MRL and submitting laboratory identifications differed, final identification by the MRL was used for the purpose of this analysis. MICs of amphotericin B, itraconazole, voriconazole, caspofungin, fluconazole, and 5-flucytosine were determined by the EUCAST broth microdilution method (30). Isolates were classified as susceptible or as showing decreased susceptibility.…”

Section: Methodsmentioning

confidence: 99%

Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003

et al. 2006

View full text Add to dashboard Cite

Candida parapsilosis has emerged as an important yeast species causing fungemia. We describe the incidence and epidemiology of C. parapsilosis fungemia. Data from active population-based surveillance in Barcelona, Spain, from January 2002 to December 2003 were analyzed. We focused on 78 episodes of C. parapsilosis fungemia, and we compared them with 175 Candida albicans controls. C. parapsilosis accounted for 23% of all fungemias. The annual incidences were 1 episode per 10 5 patients, 1.2 episodes per 10 4 discharges, and 1.7 episodes per 10 5 patient days. All isolates but one (99%) were fluconazole susceptible. Seventy-two isolates (92%) were inpatient candidemias. Forty-two episodes (51%) were considered catheter-related fungemia, 35 (45%) were considered primary fungemia, and 3 (4%) were considered secondary fungemia. Risk factors for candidemia were vascular catheterization (97%), prior antibiotic therapy (91%), parenteral nutrition (54%), prior surgery (46%), prior immunosuppressive therapy (38%), malignancy (27%), prior antifungal infection (26%), transplant recipient (16%), neutropenia (12%), and prior colonization (11%). Multivariate analysis of the differential characteristics showed that the factors that independently predicted the presence of C. parapsilosis fungemia were neonate patients (odds ratio [OR], 7.5; 95% confidence interval [CI], 2.1 to 26.8; P ‫؍‬ 0.002), transplant recipients (OR, 9.2; 95% CI, 1.9 to 43.3; P ‫؍‬ 0.005), patients with a history of prior antifungal therapy (OR, 5.4; 95% CI, 1.8 to 15.9; P ‫؍‬ 0.002), and patients who received parenteral nutrition (OR, 2.2; 95% CI, 1.09 to 4.6; P ‫؍‬ 0.028). The overall mortality rate was lower than that associated with C. albicans candidemia (23% versus 43%; P < 0.01). In summary, C. parapsilosis was responsible for 23% of all candidemias and was more frequent in neonates, in transplant recipients, and in patients who received parenteral nutrition or previous antifungal therapy, mainly fluconazole. The mortality rate was lower than that associated with C. albicans fungemia.

show abstract

Section: Methodsmentioning

confidence: 99%

Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003

et al. 2006

View full text Add to dashboard Cite

show abstract

“…However, treatment was switched to amphotericin B (3 mg/kg of body weight/day) for 3 weeks after antifungal drug susceptibility testing results (ATBFungus3; bioMerieux) showed decreased susceptibility to all of the antifungals tested, except amphotericin B. MICs of amphotericin B (0.5 g/ml), flucytosine (8 g/ml), fluconazole (64 g/ml), voriconazole (2 g/ml), posaconazole (0.5 g/ml), and caspofungin (Ͼ8 g/ml) were determined according to the EUCAST microdilution broth reference method (28). The inflammatory markers then returned to normal levels.…”

Section: Case Reportmentioning

confidence: 99%

Peritonitis Due to Blastobotrys proliferans in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The spectrophotometric approach to antifungal susceptibility testing has indeed been shown to be valid and feasible for use in the clinical laboratory (9)(10)(11) and is an integral component of the European Committee on Antibiotic Susceptibility Testing BMD method (8,39). Until recently, spectrophotometry has not been incorporated into any commercially available testing method, leaving laboratories to contend with a nonautomated approach to antifungal susceptibility testing that is considered by many to be difficult and tedious to perform (25,34).…”

mentioning

confidence: 99%

Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp

et al. 2007

View full text Add to dashboard Cite

A fully automated commercial antifungal susceptibility test system (VITEK 2; bioMérieux, Inc., Hazelwood, MO) was compared in three different laboratories with the Clinical and Laboratory Standards Institute (formerly the NCCLS) reference broth microdilution method (BMD) by testing 2 quality control strains, 10 reproducibility strains, and 426 isolates of Candida spp. against amphotericin B, flucytosine, and voriconazole. Reference BMD MIC endpoints were established after 24 and 48 h of incubation. VITEK 2 system MIC endpoints were determined spectrophotometrically after 9.1 to 27.1 h of incubation (mean, 12 to 14 h). Excellent essential agreement (within 2 dilutions) between the VITEK 2 system and the 24-and 48-h BMD MICs was observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respectively; flucytosine, 99.1% and 98.8%, respectively; and voriconazole, 96.7% and 96%, respectively. Both intra-and interlaboratory agreements were >98% for all three drugs. The overall categorical agreements between the VITEK 2 system and BMD for flucytosine and voriconazole were 98.1 to 98.6% at the 24-h BMD time point and 96.9 to 97.4% at the 48-h BMD time point. The VITEK 2 system reliably detected flucytosine and voriconazole resistance among Candida spp. and demonstrated excellent quantitative and qualitative agreement with the reference BMD method.

show abstract

Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts

Cited by 162 publications

References 12 publications

Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003

Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003

Peritonitis Due to Blastobotrys proliferans in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis

Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp

Contact Info

Product

Resources

About